

Sample Appeal Letter

Re:

To whom it may concern:

We have reviewed and recognize your guidelines for the responsible management of medications within this class. We are requesting that you reassess your recent denial of Olumiant® (baricitinib) coverage. We understand that the reason for your denial is

However, we believe that Olumiant is the appropriate treatment for the patient.

In support of our recommendation for Olumiant treatment, we have provided an overview of the patient's relevant clinical history below.

Patient's diagnosis*:

Patient's history, diagnosis, condition, and symptoms:

Please provide the following:

Primary ICD-10 diagnosis code _____ Other ICD-10 diagnosis code (if applicable) _____

A _____ has either been consulted or is the prescribing physician for Olumiant

Please detail all past treatments:

Treatment	Dose	Start/stop dates	Reason(s) for discontinuation
-----------	------	------------------	-------------------------------

Additional patient comorbidities or considerations:

Supporting references for the recommendation:

Physician contact information:

Please feel free to contact me, _____, at _____ or _____ for any additional information you may require. We look forward to receiving your timely response and approval of this claim.

Sincerely,

Patient's name and signature if required by payer

Encl: Medical records, supporting documentation, Letter of Medical Necessity, original denial letter



Please click to access full [Prescribing Information](#), including [Boxed Warning](#), and [Medication Guide](#).

Olumiant® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Olumiant Together™ is a trademark of Eli Lilly and Company.

PP-BA-US-1737 06/2022 © Lilly USA, LLC 2022. All rights reserved.